YTB323 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-24 in 3mo
ESTIMATED |
READOUT
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323
Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis |
NVS NOVARTIS AG | YTB323 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|